Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients

World Journal of Gastroenterology

Volumn 21, Issue 5, 2015, Pages 1457-1467

  Bae, Jeong Mo ^a   Lee, Tae Hun ^a   Cho, Nam Yun ^a   Kim, Tae You ^a   Kang, Gyeong Hoon ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

CDX2; Colorectal cancer; CpG island methylator phenotype; Microsatellite instability; Survival

Indexed keywords

B RAF KINASE; CYTOKERATIN 20; CYTOKERATIN 7; FLUOROURACIL; K RAS PROTEIN; TRANSCRIPTION FACTOR CDX2; CDX2 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; CPG ISLAND; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; OVERALL SURVIVAL; PHENOTYPE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; CANCER STAGING; CHEMISTRY; CHI SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; DISEASE COURSE; DISEASE FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; MUTATION; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CHI-SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DOWN-REGULATION; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84922569390     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i5.1457     Document Type: Article

References (51)

1. Sung JJ, Lau JY, Goh KL, Leung WK. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol 2005; 6: 871-876 [PMID: 16257795 DOI: 10.1016/S1470-2045(05)70422-8]
2. Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH, Lee JS. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011. Cancer Res Treat 2014; 46: 109-123 [PMID: 24851102 DOI: 10.4143/crt.2014.46.2.109]
3. Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, Liao X, Waldron L, Hoshida Y, Huttenhower C, Chan AT, Giovannucci E, Fuchs C, Ogino S. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012; 61: 847-854 [PMID: 22427238 DOI: 10.1136/gutjnl-2011-300865]
4. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337 [PMID: 22810696 DOI: 10.1038/nature11252]
5. Silberg DG, Swain GP, Suh ER, Traber PG. Cdx1 and cdx2 expression during intestinal development. Gastroenterology 2000; 119: 961-971 [PMID: 11040183]
6. Guo RJ, Suh ER, Lynch JP. The role of Cdx proteins in intestinal development and cancer. Cancer Biol Ther 2004; 3: 593-601 [PMID: 15136761]
7. Gao N, White P, Kaestner KH. Establishment of intestinal identity and epithelial-mesenchymal signaling by Cdx2. Dev Cell 2009; 16: 588-599 [PMID: 19386267 DOI: 10.1016/j.devcel.2009.02.010]
8. Macdonald PM, Struhl G. A molecular gradient in early Drosophila embryos and its role in specifying the body pattern. Nature 1986; 324: 537-545 [PMID: 2878369 DOI: 10.1038/324537a0]
9. James R, Erler T, Kazenwadel J. Structure of the murine homeobox gene cdx-2. Expression in embryonic and adult intestinal epithelium. J Biol Chem 1994; 269: 15229-15237 [PMID: 7910823]
10. Boudreau F, Rings EH, van Wering HM, Kim RK, Swain GP, Krasinski SD, Moffett J, Grand RJ, Suh ER, Traber PG. Hepatocyte nuclear factor-1 alpha, GATA-4, and caudal related homeodomain protein Cdx2 interact functionally to modulate intestinal gene transcription. Implication for the developmental regulation of the sucrase-isomaltase gene. J Biol Chem 2002; 277: 31909-31917 [PMID: 12060663 DOI: 10.1074/jbc.M204622200]
11. Jedlicka P, Sui X, Sussel L, Gutierrez-Hartmann A. Ets transcription factors control epithelial maturation and transit and crypt-villus morphogenesis in the mammalian intestine. Am J Pathol 2009; 174: 1280-1290 [PMID: 19264912 DOI: 10.2353/ajpath.2009.080409]
12. Boyd M, Bressendorff S, Moller J, Olsen J, Troelsen JT. Mapping of HNF4alpha target genes in intestinal epithelial cells. BMC Gastroenterol 2009; 9: 68 [PMID: 19761587 DOI: 10.1186/1471-230X-9-68]
13. Stegmann A, Hansen M, Wang Y, Larsen JB, Lund LR, Ritié L, Nicholson JK, Quistorff B, Simon-Assmann P, Troelsen JT, Olsen J. Metabolome, transcriptome, and bioinformatic cis-element analyses point to HNF-4 as a central regulator of gene expression during enterocyte differentiation. Physiol Genomics 2006; 27: 141-155 [PMID: 16868071 DOI: 10.1152/physiolgenomics.00314.2005]
14. Jonckheere N, Vincent A, Perrais M, Ducourouble MP, Male AK, Aubert JP, Pigny P, Carraway KL, Freund JN, Renes IB, Van Seuningen I. The human mucin MUC4 is transcriptionally regulated by caudal-related homeobox, hepatocyte nuclear factors, forkhead box A, and GATA endodermal transcription factors in epithelial cancer cells. J Biol Chem 2007; 282: 22638-22650 [PMID: 17553805 DOI: 10.1074/jbc.M700905200]
15. Kaimaktchiev V, Terracciano L, Tornillo L, Spichtin H, Stoios D, Bundi M, Korcheva V, Mirlacher M, Loda M, Sauter G, Corless CL. The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod Pathol 2004; 17: 1392-1399 [PMID: 15205684 DOI: 10.1038/modpathol.3800205]
16. Aoki K, Tamai Y, Horiike S, Oshima M, Taketo MM. Colonic polyposis caused by mTOR-mediated chromosomal instability in Apc+/Delta716 Cdx2+/- compound mutant mice. Nat Genet 2003; 35: 323-330 [PMID: 14625550 DOI: 10.1038/ng1265]
17. Bonhomme C, Duluc I, Martin E, Chawengsaksophak K, Chenard MP, Kedinger M, Beck F, Freund JN, Domon-Dell C. The Cdx2 homeobox gene has a tumour suppressor function in the distal colon in addition to a homeotic role during gut development. Gut 2003; 52: 1465-1471 [PMID: 12970140]
18. Aoki K, Kakizaki F, Sakashita H, Manabe T, Aoki M, Taketo MM. Suppression of colonic polyposis by homeoprotein CDX2 through its nontranscriptional function that stabilizes p27Kip1. Cancer Res 2011; 71: 593-602 [PMID: 21224344 DOI: 10.1158/0008-5472.can-10-2842]
19. Guo RJ, Funakoshi S, Lee HH, Kong J, Lynch JP. The intestine-specific transcription factor Cdx2 inhibits beta-catenin/TCF transcriptional activity by disrupting the beta-catenin-TCF protein complex. Carcinogenesis 2010; 31: 159-166 [PMID: 19734199 DOI: 10.1093/carcin/bgp213]
20. Moskaluk CA, Zhang H, Powell SM, Cerilli LA, Hampton GM, Frierson HF. Cdx2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays. Mod Pathol 2003; 16: 913-919 [PMID: 13679455 DOI: 10.1097/01.mp.0000086073.92773.55]
21. Baba Y, Nosho K, Shima K, Freed E, Irahara N, Philips J, Meyerhardt JA, Hornick JL, Shivdasani RA, Fuchs CS, Ogino S. Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer. Clin Cancer Res 2009; 15: 4665-4673 [PMID: 19584150 DOI: 10.1158/1078-0432.CCR-09-0401]
22. Matsuda M, Sentani K, Noguchi T, Hinoi T, Okajima M, Matsusaki K, Sakamoto N, Anami K, Naito Y, Oue N, Yasui W. Immunohistochemical analysis of colorectal cancer with gastric phenotype: claudin-18 is associated with poor prognosis. Pathol Int 2010; 60: 673-680 [PMID: 20846265 DOI: 10.1111/j.1440-1827.2010.02587.x]
23. Hinoi T, Tani M, Lucas PC, Caca K, Dunn RL, Macri E, Loda M, Appelman HD, Cho KR, Fearon ER. Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon. Am J Pathol 2001; 159: 2239-2248 [PMID: 11733373 DOI: 10.1016/s0002- 9440(10)63074-x]
24. Rozek LS, Lipkin SM, Fearon ER, Hanash S, Giordano TJ, Greenson JK, Kuick R, Misek DE, Taylor JM, Douglas JA, Rennert G, Gruber SB. CDX2 polymorphisms, RNA expression, and risk of colorectal cancer. Cancer Res 2005; 65: 5488-5492 [PMID: 15994917 DOI: 10.1158/0008-5472.can-04-3645]
25. Zlobec I, Bihl M, Foerster A, Rufle A, Lugli A. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features. J Pathol 2011; 225: 336-343 [PMID: 21660972 DOI: 10.1002/path.2879]
26. Olsen J, Espersen ML, Jess P, Kirkeby LT, Troelsen JT. The clinical perspectives of CDX2 expression in colorectal cancer: a qualitative systematic review. Surg Oncol 2014; 23: 167-176 [PMID: 25126956 DOI: 10.1016/j.suronc.2014.07.003]
27. Hong KD, Lee D, Lee Y, Lee SI, Moon HY. Reduced CDX2 expression predicts poor overall survival in patients with colorectal cancer. Am Surg 2013; 79: 353-360 [PMID: 23574843]
28. Bae JM, Kim JH, Cho NY, Kim TY, Kang GH. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location. Br J Cancer 2013; 109: 1004-1012 [PMID: 23900220 DOI: 10.1038/bjc.2013.430]
29. Lugli A, Tzankov A, Zlobec I, Terracciano LM. Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status. Mod Pathol 2008; 21: 1403-1412 [PMID: 18587323 DOI: 10.1038/modpathol.2008.117]
30. Kim JH, Shin SH, Kwon HJ, Cho NY, Kang GH. Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. Virchows Arch 2009; 455: 485-494 [PMID: 19911194 DOI: 10.1007/s00428-009-0857-0]
31. Werling RW, Yaziji H, Bacchi CE, Gown AM. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 2003; 27: 303-310 [PMID: 12604886]
32. Dawson H, Galván JA, Helbling M, Muller DE, Karamitopoulou E, Koelzer VH, Economou M, Hammer C, Lugli A, Zlobec I. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency. Int J Cancer 2014; 134: 2342-2351 [PMID: 24166180 DOI: 10.1002/ijc.28564]
33. Borrisholt M, Nielsen S, Vyberg M. Demonstration of CDX2 is highly antibody dependant. Appl Immunohistochem Mol Morphol 2013; 21: 64-72 [PMID: 22595949 DOI: 10.1097/PAI.0b013e318257f8aa]
34. Sivagnanasundaram S, Islam I, Talbot I, Drummond F, Walters JR, Edwards YH. The homeobox gene CDX2 in colorectal carcinoma: a genetic analysis. Br J Cancer 2001; 84: 218-225 [PMID: 11161380 DOI: 10.1054/bjoc.2000.1544]
35. Yagi OK, Akiyama Y, Yuasa Y. Genomic structure and alterations of homeobox gene CDX2 in colorectal carcinomas. Br J Cancer 1999; 79: 440-444 [PMID: 10027310 DOI: 10.1038/sj.bjc.6690068]
36. Woodford-Richens KL, Halford S, Rowan A, Bevan S, Aaltonen LA, Wasan H, Bicknell D, Bodmer WF, Houlston RS, Tomlinson IP. CDX2 mutations do not account for juvenile polyposis or Peutz-Jeghers syndrome and occur infrequently in sporadic colorectal cancers. Br J Cancer 2001; 84: 1314-1316 [PMID: 11355940 DOI: 10.1054/bjoc.2001.1800]
37. Wicking C, Simms LA, Evans T, Walsh M, Chawengsaksophak K, Beck F, Chenevix-Trench G, Young J, Jass J, Leggett B, Wainwright B. CDX2, a human homologue of Drosophila caudal, is mutated in both alleles in a replication error positive colorectal cancer. Oncogene 1998; 17: 657-659 [PMID: 9704932 DOI: 10.1038/sj.onc.1201971]
38. Hinoi T, Loda M, Fearon ER. Silencing of CDX2 expression in colon cancer via a dominant repression pathway. J Biol Chem 2003; 278: 44608-44616 [PMID: 12947088 DOI: 10.1074/jbc. M307435200]
39. Benahmed F, Gross I, Gaunt SJ, Beck F, Jehan F, Domon-Dell C, Martin E, Kedinger M, Freund JN, Duluc I. Multiple regulatory regions control the complex expression pattern of the mouse Cdx2 homeobox gene. Gastroenterology 2008; 135: 1238-1247, 1247. e1-e3 [PMID: 18655789 DOI: 10.1053/j.gastro.2008.06.045]
40. Saandi T, Baraille F, Derbal-Wolfrom L, Cattin AL, Benahmed F, Martin E, Cardot P, Duclos B, Ribeiro A, Freund JN, Duluc I. Regulation of the tumor suppressor homeogene Cdx2 by HNF4α in intestinal cancer. Oncogene 2013; 32: 3782-3788 [PMID: 22986531 DOI: 10.1038/onc.2012.401]
41. Shida Y, Fujimori T, Tanaka H, Fujimori Y, Kimura R, Ueda H, Ichikawa K, Tomita S, Nagata H, Kubota K, Tsubaki M, Kato H, Yao T, Sugai T, Sugihara K, Ohkura Y, Imura J. Clinicopathological features of serrated adenocarcinoma defined by Mäkinen in dukes' B colorectal carcinoma. Pathobiology 2012; 79: 169-174 [PMID: 22433973 DOI: 10.1159/000334837]
42. Juo YY, Johnston FM, Zhang DY, Juo HH, Wang H, Pappou EP, Yu T, Easwaran H, Baylin S, van Engeland M, Ahuja N. Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. Ann Oncol 2014; 25: 2314-2327 [PMID: 24718889 DOI: 10.1093/annonc/mdu149]
43. Walsh MD, Clendenning M, Williamson E, Pearson SA, Walters RJ, Nagler B, Packenas D, Win AK, Hopper JL, Jenkins MA, Haydon AM, Rosty C, English DR, Giles GG, McGuckin MA, Young JP, Buchanan DD. Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype. Mod Pathol 2013; 26: 1642-1656 [PMID: 23807779 DOI: 10.1038/modpathol.2013.101]
44. Tsai JH, Lin YL, Cheng YC, Chen CC, Lin LI, Tseng LH, Cheng ML6, Liau JY1, Jeng YM. Aberrant expression of annexin A10 is closely related to gastric phenotype in serrated pathway to colorectal carcinoma. Mod Pathol 2014; Epub ahead of print [PMID: 25081749 DOI: 10.1038/modpathol.2014.96]
45. Dawson H, Koelzer VH, Lukesch AC, Mallaev M, Inderbitzin D, Lugli A, Zlobec I. Loss of Cdx2 Expression in Primary Tumors and Lymph Node Metastases is Specific for Mismatch Repair-Deficiency in Colorectal Cancer. Front Oncol 2013; 3: 265 [PMID: 24130965 DOI: 10.3389/fonc.2013.00265]
46. Dahlin AM, Palmqvist R, Henriksson ML, Jacobsson M, Eklöf V, Rutegård J, Oberg A, Van Guelpen BR. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clin Cancer Res 2010; 16: 1845-1855 [PMID: 20197478 DOI: 10.1158/1078-0432.ccr-09-2594]
47. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009; 58: 90-96 [PMID: 18832519 DOI: 10.1136/gut.2008.155473]
48. English DR, Young JP, Simpson JA, Jenkins MA, Southey MC, Walsh MD, Buchanan DD, Barker MA, Haydon AM, Royce SG, Roberts A, Parry S, Hopper JL, Jass JJ, Giles GG. Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype. Cancer Epidemiol Biomarkers Prev 2008; 17 : 1774-1780 [PMID: 18628431 DOI: 10.1158/1055-9965.epi-08-0091]
49. Karamitopoulou E, Zlobec I, Panayiotides I, Patsouris ES, Peros G, Rallis G, Lapas C, Karakitsos P, Terracciano LM, Lugli A. Systematic analysis of proteins from different signaling pathways in the tumor center and the invasive front of colorectal cancer. Hum Pathol 2011; 42 : 1888-1896 [PMID: 21664646 DOI: 10.1016/j.humpath.2010.06.020]
50. Subramanian J, Simon R. Overfitting in prediction models - is it a problem only in high dimensions? Contemp Clin Trials 2013; 36: 636-641 [PMID: 23811117 DOI: 10.1016/j.cct.2013.06.011]
51. Hernández B, Parnell A, Pennington SR. Why have so few proteomic biomarkers "survived" validation? (Sample size and independent validation considerations). Proteomics 2014; 14: 1587-1592 [PMID: 24737731 DOI: 10.1002/pmic.201300377]